Vor Biopharma (NYSE:VOR) Price Target Lowered to $14.00 at Robert W. Baird

Vor Biopharma (NYSE:VOR - Get Free Report) had its price objective dropped by equities research analysts at Robert W. Baird from $22.00 to $14.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock.

VOR has been the topic of a number of other research reports. Barclays cut their price target on shares of Vor Biopharma from $10.00 to $3.00 and set an "overweight" rating on the stock in a report on Wednesday, August 14th. JMP Securities reaffirmed a "market outperform" rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Friday, September 6th. Finally, HC Wainwright reissued a "buy" rating and issued a $17.50 target price on shares of Vor Biopharma in a report on Friday, September 6th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $11.36.

Vor Biopharma Stock Performance

Shares of NYSE VOR traded up $0.12 during trading on Friday, hitting $0.96. 781,368 shares of the company traded hands, compared to its average volume of 504,849. The business's fifty day moving average is $0.80 and its 200 day moving average is $1.08. Vor Biopharma has a fifty-two week low of $0.63 and a fifty-two week high of $3.14. The firm has a market capitalization of $65.53 million, a price-to-earnings ratio of -0.48 and a beta of -0.40.

Vor Biopharma (NYSE:VOR - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.41). On average, analysts predict that Vor Biopharma will post -1.51 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Rosalind Advisors Inc. acquired a new stake in Vor Biopharma in the 3rd quarter valued at $54,000. Exchange Traded Concepts LLC boosted its holdings in Vor Biopharma by 40.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company's stock valued at $116,000 after purchasing an additional 48,017 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Vor Biopharma in the second quarter worth approximately $53,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vor Biopharma during the 2nd quarter worth about $63,000. Finally, Hsbc Holdings PLC increased its position in shares of Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company's stock valued at $51,000 after acquiring an additional 31,333 shares during the last quarter. Institutional investors and hedge funds own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.